Slides and Webcasts from all ESMO Preceptorships are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO - The Christie Preceptorship on Lung Cancer 2025: Manchester
- Start date
- 12 Mar 2025
- End date
- 14 Mar 2025
- Location
- Manchester, United Kingdom
Learning objectives
- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies
Travel grant
In addition to the course registration, a travel grant of maximum 600 euros is offered to non-local participants as a contribution versus their accommodation and travel costs (excluding Visa costs).
Participants must supply proof of the costs as appropriate (tickets and receipts/invoices).
The reimbursement of travel costs will be processed after the course according to the rules below:
Distance |
Reimbursement per return trip |
|---|---|
Up to 100 km |
EUR 70.00 |
101 > 399 km |
EUR 150.00 |
> 400 km |
Please visit this page and use the rail or flight calculator by inserting the city of departure and the city of arrival; then refer to Table 2 (on the same page) to check the reimbursement amount corresponding to the calculated distance. |
*Place of work | |
Accreditation
The programme of this event will be accredited with 16 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Supported by
